Literature DB >> 3044424

Effect of bile on cyclosporin absorption in liver transplant patients.

M U Mehta1, R Venkataramanan, G J Burckart, R J Ptachcinski, B Delamos, S Stachak, D H Van Thiel, S Iwatsuki, T E Starzl.   

Abstract

1. We quantitated the effect of biliary diversion on cyclosporin (CyA) absorption in liver transplant patients. Multiple blood samples were obtained over one dosing interval following oral CyA administration in eight liver transplant patients before and after T-tube clamping. 2. Cyclosporin concentrations were measured by a high pressure liquid chromatographic method. 3. The mean (+/- s.d.) dose-normalized area under the blood concentration vs time curve (AUC) over a dosing interval was 5.23 (+/- 3.22) ng ml-1 h during the pre clamping period and 15.79 +/- 7.92 ng ml-1 h during the post clamping period. A significant (P less than 0.05) increase (276%) in the dose normalized AUC was observed following the T-tube clamping. 4. Analysis of bile revealed less than 1 mg (less than 1% of dose) of unchanged CyA to be eliminated in bile over 12 h. Therefore the increased CyA AUC/dose following T-tube ligation cannot be explained by enterohepatic recirculation. 5. Increased bile flow secondary to clamping of the T-tube most likely increased the absorption of CyA. Increase in CyA absorption may be due to a bile mediated increase in CyA solubility or gastrointestinal membrane permeability, or increased residence time at the site of absorption. 6. Independent of the mechanism involved, our results indicate that adjustments in CyA dosage must be made whenever external bile diversion is instituted or discontinued.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3044424      PMCID: PMC1386431          DOI: 10.1111/j.1365-2125.1988.tb03348.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  17 in total

1.  The absorption and excretion of phenolphthalein and its glucuronide by the cat.

Authors:  K PEKANMAKI; H A SALMI
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1961

2.  Bile salt enhancement of riboflavin and flavin mononucleotide absorption in man.

Authors:  M Mayersohn; S Feldman; M Gibaldi
Journal:  J Nutr       Date:  1969-07       Impact factor: 4.798

3.  Computation of model-independent pharmacokinetic parameters during multiple dosing.

Authors:  L A Bauer; M Gibaldi
Journal:  J Pharm Sci       Date:  1983-08       Impact factor: 3.534

Review 4.  Evolution of liver transplantation.

Authors:  T E Starzl; S Iwatsuki; D H Van Thiel; J C Gartner; B J Zitelli; J J Malatack; R R Schade; B W Shaw; T R Hakala; J T Rosenthal; K A Porter
Journal:  Hepatology       Date:  1982 Sep-Oct       Impact factor: 17.425

5.  Digoxin therapy during T-tube biliary drainage in man.

Authors:  S G Carruthers; C A Dujovne
Journal:  JAMA       Date:  1978-12-15       Impact factor: 56.272

6.  Liver transplantation with use of cyclosporin a and prednisone.

Authors:  T E Starzl; G B Klintmalm; K A Porter; S Iwatsuki; G P Schröter
Journal:  N Engl J Med       Date:  1981-07-30       Impact factor: 91.245

7.  Effect of bile on vitamin B12 absorption.

Authors:  N H Teo; J M Scott; G Neale; D G Weir
Journal:  Br Med J       Date:  1980-09-27

8.  Cyclosporin-A to prevent graft-versus-host disease: a pilot study in 22 patients receiving allogeneic marrow transplants.

Authors:  P J Tutschka; W E Beschorner; A D Hess; G W Santos
Journal:  Blood       Date:  1983-02       Impact factor: 22.113

9.  Cardiac transplantation with cyclosporin A and prednisone.

Authors:  B P Griffith; R L Hardesty; G M Deeb; T E Starzl; H T Bahnson
Journal:  Ann Surg       Date:  1982-09       Impact factor: 12.969

10.  Cyclosporin A and steroid therapy in sixty-six cadaver kidney recipients.

Authors:  T E Starzl; G B Klintmalm; R Weil; K A Porter; S Iwatsuki; G P Schroter; C Fernandez-Bueno; N MacHugh
Journal:  Surg Gynecol Obstet       Date:  1981-10
View more
  26 in total

Review 1.  Pharmacokinetic drug interactions with cyclosporin (Part II).

Authors:  G C Yee; T R McGuire
Journal:  Clin Pharmacokinet       Date:  1990-11       Impact factor: 6.447

2.  Enhancement of the oral absorption of cyclosporin in man.

Authors:  J Drewe; R Meier; J Vonderscher; D Kiss; U Posanski; T Kissel; K Gyr
Journal:  Br J Clin Pharmacol       Date:  1992-07       Impact factor: 4.335

3.  Effect of hepatic dysfunction and T tube clamping on FK 506 pharmacokinetics and trough concentrations.

Authors:  A B Jain; R Venkataramanan; E Cadoff; J J Fung; S Todo; A Krajack; T E Starzl
Journal:  Transplant Proc       Date:  1990-02       Impact factor: 1.066

4.  Comparative study of cyclosporine and FK 506 dosage requirements in adult and pediatric orthotopic liver transplant patients.

Authors:  A B Jain; J J Fung; A G Tzakis; R Venkataramanan; K Abu-Elmagd; M Alessiani; J Reyes; W Irish; V Warty; S Mehta
Journal:  Transplant Proc       Date:  1991-12       Impact factor: 1.066

5.  Pharmacokinetics of FK 506 following oral administration: a comparison of FK 506 and cyclosporine.

Authors:  R Venkataramanan; A Jain; V W Warty; K Abu-Elmagd; H Furakawa; O Imventarza; J Fung; S Todo; T E Starzl
Journal:  Transplant Proc       Date:  1991-02       Impact factor: 1.066

Review 6.  Clinically significant drug interactions with cyclosporin. An update.

Authors:  C Campana; M B Regazzi; I Buggia; M Molinaro
Journal:  Clin Pharmacokinet       Date:  1996-02       Impact factor: 6.447

7.  Evaluation of pharmacokinetic interaction between cyclosporin A and probucol in rats.

Authors:  Mari Jiko; Ikuko Yano; Hiroko Wakasugi; Hideyuki Saito; Ken-ichi Inui
Journal:  Pharm Res       Date:  2002-09       Impact factor: 4.200

8.  The effect of food and bile acid administration on the relative bioavailability of cyclosporin.

Authors:  A Lindholm; S Henricsson; R Dahlqvist
Journal:  Br J Clin Pharmacol       Date:  1990-05       Impact factor: 4.335

9.  The absorption site of cyclosporin in the human gastrointestinal tract.

Authors:  J Drewe; C Beglinger; T Kissel
Journal:  Br J Clin Pharmacol       Date:  1992-01       Impact factor: 4.335

10.  Relevance of p-glycoprotein for the enteral absorption of cyclosporin A: in vitro-in vivo correlation.

Authors:  G Fricker; J Drewe; J Huwyler; H Gutmann; C Beglinger
Journal:  Br J Pharmacol       Date:  1996-08       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.